Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

IPN01194

PreclinicalSmall molecule

IPN01194 is one of 44 small molecule programs targeting Melanoma. It is currently in Preclinical.

1

Indications

1

Total Trials

1

Active Trials

43

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

MelanomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

191 competitors in Melanoma

#DrugCompanyPhaseTrials

Keytruda

Opdivo

Bristol-Myers Squibb

Mekinist

Cotellic

Zelboraf

CConrado Roberto Hoffmann Filho

Taxol

Tecentriq

Proleukin

IIovance Biotherapeutics, Inc.

Lenvima

Libtayo

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalActive, not recruiting

Melanoma

NCT06305247

Clinical

Trials by Indication[1]

Melanoma1 trial

An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours

Active, not recruiting· Ipsen logo

Ipsen·Preclinical·NCT06305247·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IPN01194. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IPN01194 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IPN01194. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Ipsen

Related News